MeSH D013920 - essential thrombocythemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Anagrelide | Anagrelide Mylan |  | 2018-02-15 |  |  |
| Roche | Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| Merck & Co | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Peginterferon alfa-2b | PegIntron |  | 2001-01-19 |  |  | |
| Ribavirin, Peginterferon alfa-2b | PegIntron/ Rebetol Combo Pack |  | 2008-06-13 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Peginterferon alfa-2b | ViraferonPeg |  | 2000-05-28 |  |  | |
| Barr Pharmaceuticals | Hydroxyurea | Hydroxyurea |  | 1998-07-30 |  |  |
| Endo | Hydroxyurea | Hydroxyurea |  | 1999-02-24 |  |  |
| Roxane Laboratories | Hydroxyurea | Hydroxyurea |  | 1995-08-18 |  |  |
| Leading Pharma | Hydroxyurea | Hydroxyurea |  | 2020-04-08 |  |  |
| Waylis Therapeutics | Hydroxyurea | Droxia |  | 1982-01-01 |  |  |
| Pharma& | Peginterferon alfa-2a | Pegasys |  | 2002-10-16 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
81%17/21
Phase 2
8%4/51
Phase 3
71%10/14
Approved: 6Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use